Home
IKT
IKT News

Latest Inhibikase Therapeutics Inc. (IKT) News on July 27, 2024

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease

GlobeNewswire

a month ago

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Business Wire

2 months ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

GlobeNewswire

2 months ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23

GlobeNewswire

2 months ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Simply Wall St.

2 months ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May

Reuters

2 months ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

AFP

2 months ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

GlobeNewswire

2 months ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Enduring role of 'treasuring the past' hailed

PR Newswire

2 months ago

Enduring role of 'treasuring the past' hailed

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

GlobeNewswire

2 months ago

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

Inhibikase Therapeutics First Quarter 2024 Earnings: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)

Simply Wall St.

2 months ago

Inhibikase Therapeutics First Quarter 2024 Earnings: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

GlobeNewswire

2 months ago

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

GlobeNewswire

2 months ago

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

GlobeNewswire

2 months ago

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

GlobeNewswire

3 months ago

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

GlobeNewswire

3 months ago

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

GlobeNewswire

4 months ago

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Inhibikase Therapeutics Full Year 2023 Earnings: EPS Misses Expectations

Simply Wall St.

4 months ago

Inhibikase Therapeutics Full Year 2023 Earnings: EPS Misses Expectations

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript

Insider Monkey

4 months ago

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

4 months ago

Q4 2023 Inhibikase Therapeutics Inc Earnings Call

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

GlobeNewswire

4 months ago

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

GlobeNewswire

5 months ago

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

GlobeNewswire

5 months ago

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now

Zacks

5 months ago

Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now

New Strong Buy Stocks for February 13th

Zacks

5 months ago

New Strong Buy Stocks for February 13th

Best Momentum Stocks to Buy for February 8th

Zacks

6 months ago

Best Momentum Stocks to Buy for February 8th

New Strong Buy Stocks for February 8th

Zacks

6 months ago

New Strong Buy Stocks for February 8th

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

GlobeNewswire

6 months ago

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

GlobeNewswire

6 months ago

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

Best Momentum Stocks to Buy for January 26th

Zacks

6 months ago

Best Momentum Stocks to Buy for January 26th

New Strong Buy Stocks for January 26th

Zacks

6 months ago

New Strong Buy Stocks for January 26th

Provident Financial Holdings To Host Earnings Release Conference Call

GlobeNewswire

6 months ago

Provident Financial Holdings To Host Earnings Release Conference Call

Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

6 months ago

Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?

Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement

PR Newswire

6 months ago

Accelerate Diagnostics Announces Pricing of Approximately $15 Million Public Offering and Private Placement

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

GlobeNewswire

6 months ago

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

7 months ago

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Despite Fast-paced Momentum, TransAct Technologies Incorporated (TACT) Is Still a Bargain Stock

Zacks

7 months ago

Despite Fast-paced Momentum, TransAct Technologies Incorporated (TACT) Is Still a Bargain Stock

Is It Smart To Buy BancFirst Corporation (NASDAQ:BANF) Before It Goes Ex-Dividend?

Simply Wall St.

7 months ago

Is It Smart To Buy BancFirst Corporation (NASDAQ:BANF) Before It Goes Ex-Dividend?

Blue Ridge Bankshares, Inc. Announces the Signing of Definitive Purchase Agreements for $150 Million in a Private Placement

PR Newswire

7 months ago

Blue Ridge Bankshares, Inc. Announces the Signing of Definitive Purchase Agreements for $150 Million in a Private Placement

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

GlobeNewswire

7 months ago

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy

ZeroFox Achieves Outstanding Recognition in G2's Winter 2024 Report, Securing Multiple Badges in Key Cybersecurity Categories

GlobeNewswire

7 months ago

ZeroFox Achieves Outstanding Recognition in G2's Winter 2024 Report, Securing Multiple Badges in Key Cybersecurity Categories

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

GlobeNewswire

7 months ago

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

CHEERS Telepathy Elevates to AI Marketing Tool for Creative Content Across the Value Chain

PR Newswire

7 months ago

CHEERS Telepathy Elevates to AI Marketing Tool for Creative Content Across the Value Chain

Director Scott Flanders' Strategic Investment in Fathom Holdings Inc

GuruFocus.com

8 months ago

Director Scott Flanders' Strategic Investment in Fathom Holdings Inc

PR Newswire

8 months ago

36Kr Holdings Inc. Reports Third Quarter 2023 Unaudited Financial Results

America’s Car-Mart, Inc. (NASDAQ:CRMT) Q2 2024 Earnings Call Transcript

Insider Monkey

8 months ago

America’s Car-Mart, Inc. (NASDAQ:CRMT) Q2 2024 Earnings Call Transcript

With 48% stake, First Community Corporation (NASDAQ:FCCO) seems to have captured institutional investors' interest

Simply Wall St.

8 months ago

With 48% stake, First Community Corporation (NASDAQ:FCCO) seems to have captured institutional investors' interest

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

GlobeNewswire

8 months ago

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

PR Newswire

8 months ago

36Kr Holdings Inc. to Report Third Quarter 2023 Financial Results on Thursday, December 7, 2023

Zacks Industry Outlook Highlights Medpace, Doximity and Biodesix

Zacks

8 months ago

Zacks Industry Outlook Highlights Medpace, Doximity and Biodesix

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

GlobeNewswire

8 months ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Intellinetics Grows Revenues 10% in Q3 2023; 27% Year-to-Date

Business Wire

8 months ago

Intellinetics Grows Revenues 10% in Q3 2023; 27% Year-to-Date

Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire

8 months ago

Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Investors Still Aren't Entirely Convinced By Nutex Health Inc.'s (NASDAQ:NUTX) Revenues Despite 27% Price Jump

Simply Wall St.

9 months ago

Investors Still Aren't Entirely Convinced By Nutex Health Inc.'s (NASDAQ:NUTX) Revenues Despite 27% Price Jump

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

GlobeNewswire

9 months ago

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

Thomson Reuters StreetEvents

9 months ago

Q3 2023 Mammoth Energy Services Inc Earnings Call

Business Wire

9 months ago

OppFi Reports Third Quarter 2023 Results, Raises Full-Year Earnings Outlook

Mammoth Energy Services Inc (TUSK) Faces Headwinds in Q3 2023 Despite Strategic Financial Moves

GuruFocus.com

9 months ago

Mammoth Energy Services Inc (TUSK) Faces Headwinds in Q3 2023 Despite Strategic Financial Moves

InfuSystem Reports Third Quarter 2023 Financial Results

Business Wire

9 months ago

InfuSystem Reports Third Quarter 2023 Financial Results

Insider Spends US$88k Buying More Shares In Summit State Bank

Simply Wall St.

9 months ago

Insider Spends US$88k Buying More Shares In Summit State Bank

Share on Social Networks: